



Consultations

Consultation on the draft 2024/25 Invitation to Tender (for public input)

23 July 2024

Overview

Pharmac | Te Pātaka Whaioranga is seeking feedback from consumers, whānau, patient support groups, consumer advocacy groups, the public, and other interested people on the draft 2024/25 Invitation to Tender.

Consultation closes at 4 pm (New Zealand standard time) on Tuesday 3 September 2024

Submit feedback through our [online form](#) or email tender@pharmac.govt.nz

We're particularly interested in feedback on:

- would a brand change for any of the medicines included in the draft tender list be not appropriate, and why?
- whether Pharmac should delay or avoid a brand change for any of these medicines and, if so, why?
- are there any features of the medicines that we should consider when evaluating them?
- what are the potential benefits, issues, or consequences of dispensing the entire prescription for any of these products all at once?
- are there potential benefits, issues, or consequences if we removed any funding restrictions from the medicine (such as Special Authority criteria)?
- which medicines, indications (uses), or population groups might need an alternative brand if a brand change were to occur and why?
- are the proposed Additional Special Terms for intra-uterine devices [Non-hormonal] (IUDs) appropriate?

We welcome any other feedback you may wish to provide. Please contact us if you wish to meet to discuss anything in this consultation.

We are also seeking feedback from healthcare professionals and suppliers.

- [Health care professionals' consultation](#)
- [Industry consultation](#)

Please share this consultation with others who you think might be interested. We want to hear feedback from a range of people.

About the annual tender

Pharmac's annual tender is used to contract for supply of medicines. Most of these medicines are already funded in New Zealand and are no longer under patent. A patent lets the inventor of a medicine own it exclusively for a set period – when that period ends, other suppliers can then make and sell that medicine.

The tender helps to secure the ongoing supply of medicines and creates savings. These savings can be used to fund new medicines.

Each year, Pharmac runs a tender which includes some of the medicines on the Pharmaceutical Schedule (the list of funded medicines). The list of medicines changes from year to year. Typically, each medicine is tendered every three years.

Before we run the tender each year, we ask for feedback from healthcare professionals, consumer groups, the pharmaceutical industry, and the public. This can tell us if:

- tendering is appropriate for each medicine
- there are any potential issues when considering a change in brand for a particular medicine.

Pharmac's [Tender Clinical Advisory Committee](#) gives us advice on every tender decision we make. The committee is made up of health care professionals, including doctors, nurse practitioners, and pharmacists. As needed, we also seek more advice from specialists in particular fields, such as cancer or mental health.

The feedback and advice we get makes sure our decisions support New Zealanders to live longer, healthier lives.

What the tender means

If we award a tender for a medicine to a pharmaceutical supplier, then that supplier's brand becomes the main funded brand of that medicine. It would likely be the only brand of that medicine funded on the Pharmaceutical Schedule. We call this "Principal Supply Status". For this tender round, Principal Supply Status would be in place until June 2028.

If the brand awarded the tender was already the only funded brand, there would be no noticeable difference for most people, although the price that Pharmac pays may change.

If that brand was one of multiple funded brands, we would move people to the brand that has been awarded the tender over time. The other brands would be removed from the Pharmaceutical Schedule. Usually, this takes five months.

If that brand was not already funded, we would move from the old brand to the new one over time. When the new brand is listed on the Pharmaceutical Schedule, the old brand remains available and funded. Then, usually after five months, the old brand is removed from the Pharmaceutical Schedule. We notify any upcoming changes at least one month before they occur.

Access to other brands if a tender is awarded to a new brand

Most people will start on, or move to, the new brand easily. However, we understand that people's experiences when taking medicines can be different. We use an "alternative brand

allowance” (ABA) to support people who may experience, or are at greater risk of, negative outcomes from a brand change. This may mean:

- moving back to the old brand after bad side effects
- having more time to change brands
- allowing some patients to avoid switching altogether.

We need to know which medicines might need alternative brands before we run the tender because we can’t guarantee continued supply of alternative brands.

We are keen to understand:

- which medicines, indications, or population groups might need an alternative brand and, if so, why?
- are there any features of the medicines that we should consider when evaluating them?

Other potential changes

The tender can result in substantial price reductions, and we can use the savings to fund new medicines. We also use the savings to fund changes to the tendered products. For example:

- if the product is currently partially funded, it could become fully funded if the tender was awarded
- the product could be added to the all-at-once (‘stat’) dispensing list, which would mean that people could collect prescriptions all at once, rather than monthly.
- we might change or remove funding restrictions so more people can use it (for example, a Special Authority restriction, endorsement, or prescriber-type restriction). We might consult on this separately before making a decision.

We are interested in your feedback on potential changes for the medicines we are tendering. You can see the Pharmaceutical Schedule for all dispensing and funding restrictions:

<https://pharmac.govt.nz/pharmaceutical-schedule>

Additional Special Terms

We have included Additional Special Terms in the draft 2024/25 Invitation to Tender contract for intra-uterine devices [Non-hormonal] (IUDs). This clause would require that potential suppliers offer education, training, and support resources to safely use the supplier’s IUD product. This could include a description of the inserter and IUD materials and insertion instructions.

Any feedback on these Additional Special Terms will help inform the final contract.

Intra-uterine device (Non-hormonal)

You shall provide the following information when submitting a Tender Bid for the Pharmaceutical intra-uterine device [Non-hormonal] (IUD Tender Item):

- *the size of the IUD Tender Item, including length and width measurements as well as the diameter of the inserter;*
- *a description of the material the inserter is made of;*
- *the duration of the therapeutic effect of the IUD Tender Item; and*
- *the metals which are contained in the IUD Tender Item.*

You shall provide the following Resources at no cost for the IUD Tender Item:

- *the provision of education, training and support to healthcare professionals in respect of the use of the IUD Tender Item.*

For the purposes of this clause “Resources” shall include but not be limited to the:

- *provision of training materials (DVDs, pamphlets, leaflets, brochures) to healthcare professionals;*
- *provision of an information sheet explaining the differences between the current brand of intra-uterine device and your IUD Tender Item; and*
- *provision of presentations and/or demonstrations on the use of your IUD Tender Item to patients and/or healthcare professionals.*

The tender list

See **Schedule Two: Products to be tendered (draft, by therapeutic group)** for the list of medicines that we are proposing to include in this year’s tender. Medicines have been grouped according to the therapeutic group classification system used in the Pharmaceutical Schedule.

A therapeutic group is a category that includes medicines used to treat similar health problems.

Below is a list of these groups, and the corresponding page numbers. Medicines that may treat multiple health problems only appear in one group.

Therapeutic group	Pages
Alimentary Tract and Metabolism	8 - 9
Blood and Blood Forming Organs	9
Cardiovascular System	10 - 11
Dermatologicals	11
Genito-Urinary System	12
Hormone Preparations	12 - 13
Infections	13 - 14
Musculoskeletal System	14
Nervous System	14 - 17
Oncology and Immunosuppressants	17
Respiratory	17 - 18
Sensory Organs	18
Various	18

Most of the items in the tender have been included in the annual tender before. However, we have not previously tendered the following products:

Tendered Item
Cladribine <ul style="list-style-type: none"> • Tab 10 mg
Desogestrel <ul style="list-style-type: none"> • Tab 75 mcg

Famotidine <ul style="list-style-type: none"> Inj 10 mg per ml, 2 ml
Fingolimod <ul style="list-style-type: none"> Cap 0.5 mg
Fulvestrant <ul style="list-style-type: none"> Inj 50 mg per ml, 5 ml
Gefitinib <ul style="list-style-type: none"> Tab 250 mg
Icatibant <ul style="list-style-type: none"> Inj 10 mg per ml, 3 ml prefilled syringe
Nilotinib <ul style="list-style-type: none"> Cap 150 mg Cap 200 mg
Nitisinone <ul style="list-style-type: none"> Cap 2 mg Cap 5 mg Cap 10 mg
Pancreatic enzyme <ul style="list-style-type: none"> Cap 420 mg
Perindopril arginine with amlodipine <ul style="list-style-type: none"> Tab perindopril arginine 10 mg with amlodipine 5 mg Tab perindopril arginine 5 mg with amlodipine 10 mg Tab perindopril arginine 5 mg with amlodipine 5 mg
Pirfenidone <ul style="list-style-type: none"> Cap 267 mg Tab 801 mg
Progesterone <ul style="list-style-type: none"> Cap 200 mg
Telmisartan with amlodipine <ul style="list-style-type: none"> Tab 40 mg with amlodipine 10 mg Tab 40 mg with amlodipine 5 mg Tab 80 mg with amlodipine 10 mg Tab 80 mg with amlodipine 5 mg

Information provided for each medicine

For each medicine (as defined by chemical name, form, and strength), we have provided, where applicable:

- the current subsidy paid per unit (such as, capsule, tablet, injection) as of 1 July 2024. These values are ex-manufacturer, excluding GST
- the number of units funded in the community in the year ending 30 June 2024 These may be partially funded or fully funded
- an estimate of the annual community-market value, based on the current subsidy paid for each unit. Pharmac estimates this by multiplying the volume of units used during the year ending 30 June 2024 by the current listed unit subsidy as at 1 July 2024
- comments relating to the tender item and/or its current listing on the Pharmaceutical Schedule.

Explanation of terms, symbols, and abbreviations

Some of the terms, abbreviations and symbols used in the draft tender list are quite specific.

Terms / abbreviations used in the draft tender list:

Term / abbreviation	Explanation
Tab	Tablet
Cap	Capsule
Liq	Liquid
Inj	Injection
Suppos	Suppository
Grans	Granules
OP	Original pack to be dispensed

Symbols used in the draft tender list:

Symbol	Explanation
<u>Underlined</u>	Tender items where there is currently a sole supply or principal supply contract are underlined. The price and subsidy for these items are fixed until 30 June 2025 unless otherwise stated in the comments column, therefore a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).
H	To be tendered for Principal Supply Status (hospital medicines).
PCT	Pharmaceuticals for which Health New Zealand Te Whatu Ora hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded product available for this tender item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP). The supplier of the successful tender bid would be required to hold additional stock.
#	A rebate currently exists.

Key dates

23 July 2024 – Consultation begins

3 September 2024 – Consultation closes

September 2024 – Tender Clinical Advisory Committee meets

Late October/Early November 2024 – Final Invitation to Tender issued

January 2025 – Earliest tender results announced

April 2025 – Earliest listing of new brands

Providing feedback

Feedback should be provided to the Tender Analysts through our [online form](#) [link] or by emailing tender@pharmac.govt.nz.

Pharmac's Board (or its delegate) will consider all feedback you send by the closing date before we finalise the 2024/25 Invitation to Tender.

Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.

We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Ascorbic acid					
Tab 100 mg	7,617,388	\$190,435	\$0.0250	C H 5%	
Bisacodyl					
Tab 5 mg	2,237,753	\$64,895	\$0.0290	C H 5%	
Budesonide					
Cap 3 mg controlled release	461,325	\$449,021	\$0.9733	C H 5%	
Calcitriol					
Cap 0.25 mcg	1,315,678	\$103,807	\$0.0789	C H 5%	
Cap 0.5 mcg	673,334	\$92,112	\$0.1368	C H 5%	
Docusate Sodium with Sennosides					
Tab 50 mg with sennosides 8 mg	70,749,220	\$1,238,111	\$0.0175	C H 5%	
Famotidine					
Inj 10 mg per ml, 2 ml				H 5%	
Inj 10 mg per ml, 4 ml	14,808			C H 5%	Note this is currently listed Cost Brand Source (CBS).
Tab 20 mg	6,879,699	\$337,793	\$0.0491	C H 5%	
Tab 40 mg	1,111,413	\$114,698	\$0.1032	C H 5%	
Ferrous Sulphate					
Tab long-acting 325 mg	12,331,780	\$1,048,201	\$0.0850	C H 5%	
Oral liq 30 mg (6 mg elemental) per ml	8,971,481	\$235,053	\$0.0262	C H 5%	
Glycerol					
Suppos 2.8/4.0 g	410,206	\$213,102	\$0.5195	C H 5%	
Glycopyrronium bromide					
Inj 0.2 mg per ml, 1 ml	56,173	\$213,457	\$3.8000	C H 5%	
Lactulose					
Oral liq 10 g per 15 ml	179,017,006	\$1,292,503	\$0.0072	C H 5%	
Loperamide hydrochloride					
Cap 2 mg	11,497,954	\$208,458	\$0.0181	C H 5%	
Multivitamins					
Tab (BPC cap strength)				H 5%	
Nitisione					
Cap 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 2 mg				H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Omeprazole					
Inf 40 mg				@ H 5%	
Inj 40 mg	9,152	\$68,420	\$7.4760	@ C H 5%	
Pancreatic enzyme					
Cap 150 mg	2,666,338	\$931,352	\$0.3493	C H 5%	Pharmac would consider bids which contain the ranges of 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-600 BP u protease.
Cap 175 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the ranges of 20,000-25,000 BP u lipase, 22,500 BP u amylase and 1250 BP u protease.
Cap 300 mg	6,765,513	\$6,385,291	\$0.9438	C H 5%	Pharmac would consider bids which contain the range of 24,000-25,000 BP u lipase, 18,000 BP u amylase and 1,000-1,500 BP u protease.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
Pancreatic enzyme						
Cap 420 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the range of 25,000-26,000 BP u lipase, 35,000 BP u amylase and 1,000-1,600 BP u protease.
Pantoprazole						
Tab EC 20 mg	13,913,843	\$307,635	\$0.0221	C H	5%	
Tab EC 40 mg	12,112,347	\$368,700	\$0.0304	C H	5%	
Sodium citrate with sodium lauryl sulphoacetate						
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	518,020	\$371,835	\$0.7178	C H	5%	
Thiamine Hydrochloride						
Tab 50 mg	13,603,330	\$632,555	\$0.0465	C H	5%	

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
Clopidogrel						
Tab 75 mg	15,231,029	\$919,345	\$0.0604	@	C H	5%
Compound electrolytes						
Powder for soln for oral use	2,917,049	\$555,990	\$0.1906		C H	5% Units and unit subsidy expressed as 'per sachet'. There may be a preference for products to include a measuring device or to come in unit dose sachets. Preference for pack sizes of 10-20 sachet packs.
Compound electrolytes with glucose [dextrose]						
Soln with electrolytes	82,650,000	\$539,705	\$0.0065		C H	5% Suppliers may submit tender bids that include one or more flavours of compound electrolytes with glucose soln. Please note product excipients for each flavour in tender bid.
Dipyridamole						
Tab or Cap long-acting 150 mg	1,100,184	\$255,430	\$0.2322		C H	5%
Heparin Sodium						
Inj 5,000 iu per ml, 5 ml	12,777	\$106,049	\$8.3000		C H	5%
Long-acting filgrastim						
Inj 6 mg per 0.6 ml	12,971	\$843,115	\$65.0000		C H	5% Units displayed as per listed pegfilgrastim.
Plerixafor						
Inj 20 mg per ml, 1.2 ml vial				#	H	5%
Sodium chloride						
inj 0.9%, 10 ml, prefilled syringe					H	5%
inj 0.9%, 3 ml, prefilled syringe					H	5%
inj 0.9%, 5 ml, prefilled syringe					H	5%
Inj 0.9%, 5 ml	104,558	\$20,912	\$0.2000		C H	5%
Inj 0.9%, 10 ml	566,764	\$59,510	\$0.1050		C H	5%
Inj 0.9%, 20 ml	183,827	\$45,957	\$0.2500		C H	5%
Tenecteplase						
Inj 50 mg					H	5%
Tranexamic acid						
Tab 500 mg	3,918,163	\$682,426	\$0.1742		C H	5%
Water for Injection						
Purified for inj, 10 ml	387,274	\$58,866	\$0.1520		C H	5%
Purified for inj, 20 ml	46,716	\$11,679	\$0.2500		C H	5%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Amiodarone hydrochloride					
<u>Inj 50 mg per ml, 3 ml</u>	13,778	\$20,970	\$1.5220	C H 5%	
<u>Tab 100 mg</u>	546,697	\$63,597	\$0.1163	C H 5%	
<u>Tab 200 mg</u>	1,251,234	\$187,272	\$0.1497	C H 5%	
Chlorthalidone [Chlorthalidone]					
<u>Tab 25 mg</u>	6,433,118	\$894,203	\$0.1390	C H 5%	
Clonidine					
<u>Tab 25 mcg</u>	5,277,217	\$1,381,523	\$0.2618	C H 5%	
Digoxin					
<u>Tab 250 mcg</u>	731,289	\$51,497	\$0.0704	C H 5%	
<u>Tab 62.5 mcg</u>	7,702,705	\$250,338	\$0.0325	C H 5%	
Diltiazem hydrochloride					
<u>Cap long-acting 120 mg</u>	7,191,559	\$939,937	\$0.1307	C H 5%	
Enalapril					
<u>Tab 5 mg</u>	3,503,255	\$68,103	\$0.0194	C H 5%	
<u>Tab 10 mg</u>	3,698,474	\$80,960	\$0.0219	C H 5%	
<u>Tab 20 mg</u>	4,631,211	\$120,921	\$0.0261	C H 5%	
Furosemide [Frusemide]					
<u>Inj 10 mg per ml, 2 ml</u>	14,769	\$7,089	\$0.4800	C H 5%	
Iloprost					
<u>Nebuliser soln 10 mcg per ml, 2 ml</u>	12,100	\$74,629	\$6.1677	C H 5%	
Labetalol					
<u>Tab 100 mg</u>	1,045,584	\$151,610	\$0.1450	C H 5%	
<u>Tab 200 mg</u>	674,177	\$182,028	\$0.2700	C H 5%	
Lisinopril					
<u>Tab 5 mg</u>	4,053,185	\$498,542	\$0.1230	C H 5%	
<u>Tab 10 mg</u>	5,592,709	\$725,207	\$0.1297	C H 5%	
<u>Tab 20 mg</u>	6,936,415	\$1,132,162	\$0.1632	C H 5%	
Losartan with hydrochlorothiazide					
<u>Tab 50 mg with hydrochlorothiazide 12.5 mg</u>	18,467,937	\$2,462,330	\$0.1333	C H 5%	
Nicorandil					
<u>Tab 10 mg</u>	980,039	\$354,941	\$0.3622	C H 5%	
<u>Tab 20 mg</u>	124,486	\$56,931	\$0.4573	C H 5%	
Nifedipine					
<u>Tab long-acting 10 mg</u>	672,399	\$233,181	\$0.3468	C H 5%	
<u>Tab long-acting 20 mg</u>	745,175	\$132,045	\$0.1772	C H 5%	
<u>Tab long-acting 30 mg</u>	601,297	\$205,241	\$0.3413	C H 5%	
<u>Tab long-acting 60 mg</u>	124,224	\$65,603	\$0.5281	C H 5%	
Nimodipine					
<u>Inj 0.2 mg per ml, 50 ml</u>				H 5%	
<u>Tab 30 mg</u>				H 5%	
Noradrenaline					
<u>Inj 1 mg per ml, 4 ml ampoule</u>			@	H 5%	
Perindopril arginine with amlodipine					
<u>Tab perindopril arginine 10 mg with amlodipine 10 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 10 mg with amlodipine 5 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 5 mg with amlodipine 10 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 5 mg with amlodipine 5 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Sotalol					
Tab 80 mg	3,934,967	\$295,123	\$0.0750	C H 5%	
Tab 160 mg	91,880	\$12,863	\$0.1400	C H 5%	
Spirolactone					
Tab 25 mg	11,391,992	\$419,225	\$0.0368	C H 5%	
Tab 100 mg	1,958,678	\$208,599	\$0.1065	C H 5%	
Telmisartan					
Tab 40 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Tab 80 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Telmisartan with amlodipine					
Tab 40 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.
Tab 40 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.
Tab 80 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.
Tab 80 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.

Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Cetomacrogol with glycerol					
<u>Crn 90% with glycerol 10%, 1,000 ml</u>	446,114,500	\$1,561,401	\$0.0035	C H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.
<u>Crn 90% with glycerol 10%, 500 ml</u>	446,114,500	\$1,561,401	\$0.0035	C H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.
Clobetasol propionate					
<u>Crn 0.05% (pack size 30 g or less)</u>	3,795,270	\$303,622	\$0.0800	C H 5%	
<u>Oint 0.05% (pack size 30 g or less)</u>	3,787,050	\$294,140	\$0.0777	C H 5%	
<u>Scalp app 0.05%</u>	975,570	\$203,572	\$0.2087	C H 5%	
Clotrimazole					
<u>Crn 1%</u>	2,822,320	\$155,228	\$0.0550	C H 5%	
Dimethicone					
<u>Crn 5% (pack size 100 g or less)</u>				H 5%	Preference for a tube pack.
<u>Lotn - head lice suffocant</u>	7,469,200	\$158,721	\$0.0213	C H 5%	Preference for a pump bottle.
<u>Crn 5% (pack size greater than 100 g)</u>	6,238,000	\$53,647	\$0.0086	C H 5%	Preference for a pump bottle.
Hydrocortisone					
<u>Crn 1% (pack size greater than or equal to 15 g and less than or equal to 100 g)</u>	14,457,652	\$857,772	\$0.0593	C H 5%	
<u>Crn 1% (pack size greater than 100 g)</u>	7,307,095	\$433,530	\$0.0593	C H 5%	
Liquid paraffin with white soft paraffin					
<u>Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)</u>				H 5%	
<u>Liquid paraffin 50% with white soft paraffin 50% ointment (pack size greater than 100 g)</u>	15,818,500	\$156,287	\$0.0099	C 5%	
Sunscreens, proprietary					
<u>SPF 50+ or greater</u>				H 5%	
Zinc and castor oil					
<u>Oint (pack size greater than or equal to 500 g)</u>	22,286,937	\$189,439	\$0.0085	C H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Genito Urinary System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Clotrimazole					
<u>Vaginal crm 1% with applicators</u>	2,013,725	\$201,373	\$0.1000	C H 5%	
<u>Vaginal crm 2% with applicators</u>	1,782,180	\$343,070	\$0.1925	C H 5%	
Desogestrel					
Tab 75 mcg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Ethinylestradiol with levonorgestrel					
<u>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tabs</u>	5,725,495	\$102,257	\$0.0179	C H 5%	
<u>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tabs</u>	20,893,431	\$373,157	\$0.0179	C H 5%	
Intra-uterine device (Non-hormonal)					
IUD Long	2,934	\$87,433	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
IUD Medium	3,666	\$109,247	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
IUD Short	2,951	\$87,940	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
Levonorgestrel					
<u>0.75 mg - 1.5 mg</u>	145,587	\$254,777	\$1.7500	C H 5%	Units shown are for tab 1.5 mg.
Oxytocin					
<u>Inj 5 iu per ml, 1 ml</u>	868	\$865	\$0.9960	C H 5%	
<u>Inj 10 iu per ml, 1 ml</u>	6,918	\$8,274	\$1.1960	C H 5%	
Oxytocin with ergometrine					
<u>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml</u>	4,773	\$30,929	\$6.4800	C H 5%	
Tamsulosin					
Tab 400 mcg	6,851,004	\$1,528,459	\$0.2231	C H 5%	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Carbimazole					
Tab 5 mg	5,408,092	\$408,852	\$0.0756	C H 5%	
Dexamethasone phosphate					
<u>Inj 4 mg per ml, 1 ml</u>	83,070	\$65,293	\$0.7860	C H 5%	Preference for a preservative free product. Pharmac reserves the right to list a preservative free product for a restricted market.
<u>Inj 4 mg per ml, 2 ml</u>	108,097	\$141,607	\$1.3100	C H 5%	Preference for a preservative free product. Pharmac reserves the right to list a preservative free product for a restricted market.
Fludrocortisone Acetate					
Tab 100 mcg	1,723,618	\$197,527	\$0.1146	C H 5%	
Progesterone					
Cap 100 mg	16,504,740	\$8,169,846	\$0.4950	C H 5%	
Cap 200 mg				C H	Not currently listed on the Schedule. Pharmac reserves the right to award one or both presentations of progesterone.
Propylthiouracil					
Tab 50 mg	267,187	\$93,515	\$0.3500	C H 5%	

Principal Sole Supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Testosterone undecanoate					
Cap 40 mg	539,239	\$194,126	\$0.3600	C H 5%	
Infections					
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Abacavir Sulphate with Lamivudine					
Tab 600 mg with lamivudine 300 mg	113,469	\$111,577	\$0.9833	C H 5%	
Aciclovir					
Tab dispersible 200 mg	565,913	\$40,293	\$0.0712	C H 5%	
Tab dispersible 400 mg	3,669,421	\$380,702	\$0.1038	C H 5%	
Tab dispersible 800 mg	318,565	\$58,798	\$0.1846	C H 5%	
Amoxicillin					
Cap 250 mg	701,404	\$60,952	\$0.0869	@ C H 5%	
Cap 500 mg	19,697,628	\$1,615,205	\$0.0820	@ C H 5%	
Atazanavir Sulphate					
Cap 150 mg	49,252	\$69,774	\$1.4167	C H 5%	
Cap 200 mg	14,156	\$25,953	\$1.8333	C H 5%	
Caspofungin					
Inj 50 mg				H 5%	
Inj 70 mg				H 5%	
Cefaclor monohydrate					
Cap 250 mg	1,262,746	\$326,420	\$0.2585	@ C H 5%	
Grans for oral liq 125 mg per 5 ml	1,833,177	\$68,744	\$0.0375	@ C H 5%	
Cefalexin monohydrate					
Cap 250 mg	441,164	\$84,924	\$0.1925	@ C H 5%	
Cap 500 mg	5,716,867	\$1,672,184	\$0.2925	@ C H 5%	
Ceftriaxone sodium					
Inj 500 mg	11,856	\$9,366	\$0.7900	@ C H 5%	
Inj 1 g	8,137	\$5,842	\$0.7180	@ C H 5%	
Inj 2 g				@ H 5%	
Clindamycin					
Inj 150 mg per ml, 4 ml ampoule	1,520	\$5,335	\$3.5100	C H 5%	
Daptomycin					
Inj 350 mg - 500 mg				H 5%	
Emtricitabine with tenofovir disoproxil					
Tab 200 mg with tenofovir disoproxil 300 mg	1,597,166	\$822,540	\$0.5150	C H 5%	
Erythromycin Lactobionate					
Inj 1 g	252	\$2,520	\$10.0000	@ C H 5%	
Methenamine (hexamine) hippurate					
Tab 1 g	5,611,246	\$1,119,444	\$0.1995	C H 5%	
Phenoxymethylpenicillin (Penicillin V)					
Grans for oral liq 125 mg per 5 ml	152,436	\$5,183	\$0.0340	@ C H 5%	
Grans for oral liq 250 mg per 5 ml	3,401,641	\$144,230	\$0.0424	@ C H 5%	
Piperacillin with Tazobactam					
Inj 2 g with tazobactam 2000/250 mg				H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award one or both presentations of piperacillin with tazobactam.
Inj 4 g with tazobactam 4000/500 mg				H 5%	Pharmac reserves the right to award one or both presentations of piperacillin with tazobactam.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy		ABA Limit	Comments
Posaconazole						
Oral liq 40 mg per ml	6,384	\$20,825	\$3.2620		C H 5%	
Tab modified-release 100 mg	50,427	\$432,832	\$8.5833		C H 5%	
Raltegravir potassium						
Tab 400 mg	75,037	\$1,363,197	\$18.1670#		C H 5%	
Tab 600 mg	113,986	\$2,070,784	\$18.1670#		C H 5%	
Tenofovir disoproxil						
Tab 300 mg	484,426	\$1,726,010	\$3.5630		C H 5%	
Trimethoprim with sulphamethoxazole [Co-trimoxazole]						
Oral liq trimethoprim and sulphamethoxazole	6,053,438	\$302,672	\$0.0500		C H 5%	
Voriconazole						
Inj 200 mg vial					H 5%	

Musculoskeletal System

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy		ABA Limit	Comments
Colchicine						
Tab 500 mcg	5,156,056	\$309,363	\$0.0600		C H 5%	Preference for blister packaging.
Risedronate sodium						
Tab 35 mg	324,189	\$202,618	\$0.6250		C H 5%	
Rocuronium bromide						
Inj 10 mg per ml, 5 ml				@	H 5%	
Tenoxicam						
Tab 20 mg	322,443	\$59,652	\$0.1850		C H 5%	
Teriparatide (current access)						
Inj 250 mcg per ml	4,193	\$817,635	\$195.0000		C H 5%	Pharmac would only award a tender for current or widened access.
Teriparatide (widened access)						
Inj 250 mcg per ml					C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for clinical vertebral fractures.
Zoledronic acid						
Inj 5 mg	2,278	\$35,651	\$15.6500		C H 5%	

Nervous System

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy		ABA Limit	Comments
Bupivacaine hydrochloride with fentanyl						
Inj 1.25mg with 2 mcg fentanyl per ml, 100 ml bag					H 5%	Preference for a product with sterile packaging.
Inj 1.25mg with 2 mcg fentanyl per ml, 200 ml bag					H 5%	Preference for a product with sterile packaging.
Bupivacaine hydrochloride with glucose						
Inj 0.5% with glucose 8%, 4 ml ampoule					H 5%	
Buprenorphine with Naloxone						
Tab sublingual 2 mg with naloxone 0.5 mg	619,564	\$260,217	\$0.4200		C H 5%	
Tab sublingual 8 mg with naloxone 2 mg	558,140	\$677,744	\$1.2143		C H 5%	
Citalopram hydrobromide						
Tab 20 mg	28,019,860	\$954,076	\$0.0341		C H 5%	
Cladribine						
Tab 10 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Codeine phosphate					
Tab 15 mg	10,827,145	\$640,967	\$0.0592	C H 5%	
Tab 30 mg	23,189,568	\$1,618,632	\$0.0698	C H 5%	
Tab 60 mg	1,462,191	\$203,098	\$0.1389	C H 5%	
Cyclizine lactate					
Inj 50 mg per ml, 1 ml ampoule	90,106	\$147,413	\$1.6360	C H 5%	
Dihydrocodeine tartrate					
Tab long-acting 60 mg	3,738,002	\$535,768	\$0.1433	C H 5%	
Domperidone					
Tab 10 mg	9,300,597	\$372,024	\$0.0400	C H 5%	
Droperidol					
Inj 2.5 mg per ml, 1 ml ampoule				H 5%	
Fingolimod					
cap 0.5 mg	116,696	\$9,168,972	\$78.5714#	C H 5%	
Fluoxetine hydrochloride					
Cap 20 mg	24,560,267	\$854,206	\$0.0348	C H 5%	
Tab dispersible 20 mg, scored	1,851,260	\$165,299	\$0.0893	C H 5%	
Levomopromazine					
Inj 25 mg per ml, 1 ml	100,900	\$247,003	\$2.4480 @	C H 5%	
Lidocaine [Lignocaine]					
Gel 2%, 10 ml - 11 ml urethral syringe	125,950	\$749,403	\$5.9500	C H 5%	Units shown are for 11ml urethral syringe.
Lidocaine [lignocaine] hydrochloride					
Spray 10 mg dose per spray				H 5%	
Gel 2%	4,832,127	\$1,063,068	\$0.2200	C H 5%	Tender is for topical gel, not urethral syringe.
Lidocaine [lignocaine] hydrochloride with adrenaline					
Inj 1% with adrenaline 1:100,000, 5 ml				H 5%	
Lithium carbonate					
cap 250 mg	2,895,703	\$647,479	\$0.2236	C H 5%	
Methadone hydrochloride					
Tab 5 mg	1,919,217	\$278,287	\$0.1450	C H 5%	
Methylphenidate hydrochloride (current access)					
Cap modified-release 10 mg	1,531,183	\$796,215	\$0.5200	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 20 mg	1,842,553	\$1,252,936	\$0.6800	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 30 mg	1,165,954	\$991,760	\$0.8506	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 40 mg	910,091	\$928,293	\$1.0200	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 60 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
Methylphenidate hydrochloride (widened access)					
Cap modified-release 10 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 20 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 30 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Methylphenidate hydrochloride (widened access)					
Cap modified-release 40 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 60 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Metoclopramide hydrochloride					
<u>Inj 5 mg per ml, 2 ml ampoule</u>	144,975	\$101,483	\$0.7000	C H 5%	
Morphine					
<u>Inj 10 mg per ml, 1 ml</u>	232,203	\$217,342	\$0.9360 @	C H 5%	
<u>Inj 15 mg per ml, 1 ml</u>	5,700	\$6,304	\$1.1060 @	C H 5%	
<u>Inj 30 mg per ml, 1 ml</u>	60,722	\$76,267	\$1.2560 @	C H 5%	
<u>Inj 5 mg per ml, 1 ml</u>	70,586	\$75,951	\$1.0760 @	C H 5%	
Morphine sulphate					
<u>Cap long-acting 10 mg</u>	4,189,681	\$1,256,904	\$0.3000	C H 5%	
<u>Cap long-acting 30 mg</u>	1,035,437	\$445,238	\$0.4300	C H 5%	
<u>Cap long-acting 60 mg</u>	296,410	\$266,769	\$0.9000	C H 5%	
<u>Cap long-acting 100 mg</u>	171,845	\$180,437	\$1.0500	C H 5%	
Nortriptyline hydrochloride					
<u>Tab 10 mg</u>	17,147,538	\$421,829	\$0.0246	C H 5%	
<u>Tab 25 mg</u>	10,039,771	\$350,790	\$0.0349	C H 5%	
Ondansetron					
<u>Tab 4 mg</u>	2,710,410	\$123,053	\$0.0454	C H 5%	
<u>Tab 8 mg</u>	797,465	\$65,392	\$0.0820	C H 5%	
Ondansetron hydrochloride					
<u>Inj 2 mg per ml, 2 ml</u>				H 5%	
<u>Inj 2 mg per ml, 4 ml</u>				H 5%	
Paracetamol					
<u>Oral liq 120 mg per 5 ml</u>	53,237,034	\$1,059,417	\$0.0199	C H 5%	Preference for a product with a syringe included.
<u>Oral liq 250 mg per 5 ml</u>	225,051,604	\$3,769,614	\$0.0168	C H 5%	Preference for a product with a syringe included.
Paracetamol with codeine					
Tab paracetamol 500 mg with codeine phosphate 15 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	43,907,260	\$1,207,450	\$0.0275	C H 5%	
Paroxetine					
<u>Tab 20 mg</u>	9,283,997	\$424,000	\$0.0457	C H 5%	
Pethidine hydrochloride					
<u>Tab 50 mg</u>	153,175	\$132,956	\$0.8680	C H 5%	
Pramipexole hydrochloride					
<u>Tab 0.25 mg</u>	2,119,168	\$116,766	\$0.0551	C H 5%	
<u>Tab 1 mg</u>	195,533	\$36,486	\$0.1866	C H 5%	
Propofol					
<u>Inj 10 mg per ml, 100 ml</u>			@	H 5%	
<u>Inj 10 mg per ml, 20 ml</u>			@	H 5%	
<u>Inj 10 mg per ml, 50 ml</u>			@	H 5%	
Ropinirole hydrochloride					
<u>Tab 0.25 mg</u>	1,785,561	\$86,082	\$0.0482	C H 5%	
<u>Tab 1 mg</u>	1,008,517	\$59,432	\$0.0589	C H 5%	
<u>Tab 2 mg</u>	358,570	\$27,660	\$0.0771	C H 5%	

Principal Sole Supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Ropinirole hydrochloride					
Tab 5 mg	30,035	\$5,185	\$0.1726	C H 5%	
Sertraline					
Tab 50 mg	25,120,860	\$828,988	\$0.0330	C H 5%	
Tab 100 mg	12,082,200	\$700,768	\$0.0580	C H 5%	
Sumatriptan					
Inj 12 mg per ml, 0.5 ml	50,788	\$756,741	\$14.9000	C H 5%	
Tetrabenazine					
Tab 25 mg	116,988	\$111,337	\$0.9517	C H 5%	

Oncology Agents and Immunosuppressants

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Azathioprine					
Tab 50 mg	3,949,005	\$319,869	\$0.0810	C H 5%	Preference for blister packaging.
Tab 25 mg	490,446	\$60,163	\$0.1227	C H 5%	Preference for blister packaging.
Bortezomib					
Inj 3.5 mg				PCT H 5%	
Capecitabine					
Tab 150 mg	130,094	\$21,248	\$0.1633	C H 5%	
Tab 500 mg	709,762	\$275,033	\$0.3875	C H 5%	
Carmustine					
Inj 100 mg vial				PCT H 5%	
Fludarabine phosphate					
Inj 50 mg				PCT H 5%	
Tab 10 mg	2,299	\$47,359	\$20.6000	PCT C H 5%	
Fulvestrant					
Inj 50 mg per ml, 5 ml	6,630	\$3,540,420	\$534.0000#	C H 5%	
Gefitinib					
Tab 250 mg	15,075	\$461,295	\$30.6000#	C H 5%	
Mercaptopurine					
Tab 50 mg	467,426	\$484,253	\$1.0360	PCT C H 5%	
Mitomycin C					
Inj 2 mg - 5 mg				PCT H 5%	
Inj 10 mg - 20 mg				PCT H 5%	
Nilotinib					
Cap 150 mg	52,432	\$2,044,848	\$39.0000#	C H 5%	
cap 200 mg	52,264	\$2,844,904	\$54.4333#	C H 5%	

Respiratory System and Allergies

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Adrenaline autoinjector					
Inj 0.15 mg per 0.3 ml	7,269	\$654,210	\$90.0000	C H 5%	
Inj 0.3 mg per 0.3 ml	26,600	\$2,394,000	\$90.0000	C H 5%	
Caffeine citrate					
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml				H 5%	
Oral liq 20 mg per ml (10 mg base per ml)	12,657	\$10,189	\$0.8050	C H 5%	
Icatibant					
Inj 10 mg per ml, 3 ml prefilled syringe	930	\$2,481,240	\$2,668.0000#	C H 5%	
Loratadine					
Tab 10 mg	40,228,419	\$716,066	\$0.0178	C H 5%	

Principal Sole Supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Respiratory System and Allergies

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy	ABA Limit	Comments	
Montelukast						
Tab 10 mg	2,346,098	\$242,985	\$0.1036	C H 5%		
Tab 4 mg	257,899	\$28,552	\$0.1107	C H 5%		
Tab 5 mg	419,283	\$46,419	\$0.1107	C H 5%		
Nintedanib						
Cap 100 mg	39,840	\$1,695,869	\$42.5670#	C H 5%		
Cap 150 mg	92,040	\$5,936,580	\$64.5000#	C H 5%		
Pirfenidone						
Cap 267 mg				C H 5%		
tab 801 mg	83,184	\$3,368,952	\$40.5000#	C H 5%		
Promethazine Hydrochloride						
Tab 10 mg	3,237,752	\$90,009	\$0.0278	C H 5%		
Tab 25 mg	5,870,176	\$185,498	\$0.0316	C H 5%		

Sensory Organs

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy	ABA Limit	Comments	
Chloramphenicol						
Eye drops 0.5%	1,652,170	\$239,565	\$0.1450	C H 5%	Units are expressed per ml.	
Eye oint 1%	723,600	\$157,745	\$0.2180	C H 5%		
Olopatadine						
Eye drops 0.1%	1,567,315	\$680,215	\$0.4340	C H 5%	For products containing Benzalkonium chloride (BAK), Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".	
Sodium cromoglicate						
Eye drops 2%	419,690	\$109,959	\$0.2620	C H 5%	Units are expressed per ml.	
Sodium hyaluronate [hyaluronic acid]						
Inj 10 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.	
Inj 14 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.	
Inj 18 mg per ml, 0.85 ml syringe				H 5%		
Inj 23 mg per ml, 0.6 ml syringe				H 5%		

Various

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy	ABA Limit	Comments	
Sodium Hypochlorite						
5% Soln				C 5%	Not currently listed on the Pharmaceutical Schedule. Preference for a child safe bottle.	